Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcopenia 1Prediabetic State 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Neoplasms 1Myelodysplastic Syndromes 1Muscle Weakness 1Leukemia, Myeloid 1Hematologic Neoplasms 1Heart Failure 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Cardiotoxicity 1Breast Neoplasms 1Anemia, Aplastic 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × nicotinamide-beta-riboside × Clear all
NCT03789175 2020-12-08

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
1 enrolled 7 charts

Neoplasms, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡